Related Experiment Video

Updated: May 8, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Pinning down myeloma with Pim2 inhibitors!

Paola Neri1, Nizar J Bahlis

  • 1University of Calgary.

Blood
|August 31, 2013
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Related Experiment Videos

Last Updated: May 8, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.

Nature medicine·2026

Longitudinal mechanisms of response, resistance and relapse to teclistamab in multiple myeloma: results from MajesTEC-1.

Haematologica·2026

Daratumumab in transplant-ineligible or -deferred newly diagnosed multiple myeloma: minimal residual disease in CEPHEUS.

Blood advances·2026

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.

The New England journal of medicine·2026

Smoldering Multiple Myeloma: From Clinical to Immunogenomic Risk Stratification and Therapeutic Implications of Early Intervention.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026

Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE.

Blood advances·2026

Measurable Residual Disease-Dependent Unfavorable Outcomes in Pediatric PAX5-Rearranged B-Acute Lymphoblastic Leukemia.

Blood·2026

The hepatic FGFR-ERK-HRG axis regulates heparin-induced thrombocytopenia with thrombosis.

Blood·2026

HOW I TREAT BLEEDING IN WOMEN AND GIRLS WITH HEMOPHILIA/ HEMOPHILIA CARRIERS.

Blood·2026

FERMT3 alternative splicing enhances kindlin-3 membrane recruitment for neutrophil adhesion during stress myelopoiesis.

Blood·2026

Risk of recurrence in patients with provoked venous thromboembolism: a prospective cohort study.

Blood·2026

How I treat autoimmune neutropenia in adults.

Blood·2026

Control of Intraocular Metastases of ALK-Rearranged Non-Small Cell Lung Cancer with Sequential Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: A Report of 2 Cases and Review of the Literature.

Case reports in oncology·2026

TP53 mutation drives unique transcriptional and functional vulnerabilities independent of del(17p) in multiple myeloma.

iScience·2026

Immunotherapy Efficacy in SMARC-Altered Cancers: A pan-cancer analysis of clinical outcomes in response to immune checkpoint inhibition.

iScience·2026

Hierarchical ROS-scavenging hydrogel system for coordinating the modulation of RGC necroptosis and oxidative stress in an acute glaucoma model.

Bioactive materials·2026

Does Combination Therapy With a Glucagon-Like Peptide-1 Receptor Agonist and a Sodium-Glucose Cotransporter 2 Inhibitor Enhance Cardiovascular and Renal Protection in People With Type 2 Diabetes Mellitus?

Cureus·2026

Arctigenin discovered by high-throughput screening ameliorates doxorubicin-induced cardiotoxicity as a novel natural KEAP1-NRF2 inhibitor.

Journal of pharmaceutical analysis·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us